Toward predictors of survival in castration-resistant prostate cancer

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Overall survival is a widely accepted endpoint in phase 3 clinical trials of castration-resistant prostate cancer (CRPC). However, the use of this endpoint is becoming more difficult as more agents are shown to improve survival in patients with CRPC. This editorial describes the commonly used surrogates for overall survival in CRPC with a special emphasis on radiographic response.

Original languageEnglish (US)
Pages (from-to)3882-3884
Number of pages3
JournalCancer
Volume117
Issue number17
DOIs
StatePublished - Sep 1 2011

Fingerprint

Castration
Prostatic Neoplasms
Survival
Phase III Clinical Trials

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Toward predictors of survival in castration-resistant prostate cancer. / Graff, Julie; Beer, Tomasz (Tom).

In: Cancer, Vol. 117, No. 17, 01.09.2011, p. 3882-3884.

Research output: Contribution to journalArticle

@article{91f1fa4757e54dc697adebadafc43b98,
title = "Toward predictors of survival in castration-resistant prostate cancer",
abstract = "Overall survival is a widely accepted endpoint in phase 3 clinical trials of castration-resistant prostate cancer (CRPC). However, the use of this endpoint is becoming more difficult as more agents are shown to improve survival in patients with CRPC. This editorial describes the commonly used surrogates for overall survival in CRPC with a special emphasis on radiographic response.",
author = "Julie Graff and Beer, {Tomasz (Tom)}",
year = "2011",
month = "9",
day = "1",
doi = "10.1002/cncr.25986",
language = "English (US)",
volume = "117",
pages = "3882--3884",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "17",

}

TY - JOUR

T1 - Toward predictors of survival in castration-resistant prostate cancer

AU - Graff, Julie

AU - Beer, Tomasz (Tom)

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Overall survival is a widely accepted endpoint in phase 3 clinical trials of castration-resistant prostate cancer (CRPC). However, the use of this endpoint is becoming more difficult as more agents are shown to improve survival in patients with CRPC. This editorial describes the commonly used surrogates for overall survival in CRPC with a special emphasis on radiographic response.

AB - Overall survival is a widely accepted endpoint in phase 3 clinical trials of castration-resistant prostate cancer (CRPC). However, the use of this endpoint is becoming more difficult as more agents are shown to improve survival in patients with CRPC. This editorial describes the commonly used surrogates for overall survival in CRPC with a special emphasis on radiographic response.

UR - http://www.scopus.com/inward/record.url?scp=80051939662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051939662&partnerID=8YFLogxK

U2 - 10.1002/cncr.25986

DO - 10.1002/cncr.25986

M3 - Article

C2 - 21391212

AN - SCOPUS:80051939662

VL - 117

SP - 3882

EP - 3884

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 17

ER -